CD133 Expression in Mammary Invasive Ductal Carcinoma
Significance of CD133 Expression in Invasive Ductal Carcinoma of the Breast
1 other identifier
observational
50
1 country
2
Brief Summary
Background and Aim: Breast carcinoma is the most common type of cancer and the most common cause of cancer-related mortality among women worldwide. Cancer stem cells (CSCs) are thought to be responsible for tumor initiation, progression, dissemination and resistance to chemotherapy and radiotherapy. CD133 is a trans-membrane glycoprotein which is considered as a putative CSCs marker. It has been extensively used as a stem cell marker for normal and cancerous tissues. Emerging evidence suggests that CD133 may be a critical factor in tumor development, progression and metastasis. The aim of this study was to evaluate expression status of CD133 in invasive ductal carcinoma (IDC) of the breast and its role during breast cancer progression and to correlate its expression with some known clinicopathological parameters.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for all trials
Started May 2021
Shorter than P25 for all trials
2 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
April 30, 2021
CompletedStudy Start
First participant enrolled
May 1, 2021
CompletedFirst Posted
Study publicly available on registry
May 5, 2021
CompletedPrimary Completion
Last participant's last visit for primary outcome
November 1, 2021
CompletedStudy Completion
Last participant's last visit for all outcomes
December 1, 2021
CompletedMay 10, 2021
May 1, 2021
6 months
April 30, 2021
May 5, 2021
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
1. Detect the immunohistochemical expression of CD133 in mammary invasive ductal carcinoma (IDC) and to correlate its expression with some known clinicopathological parameters.
1 month
Secondary Outcomes (1)
2. Correlate the IHC expression of CD133 with some known clinicopathological parameters in mammary IDC.
1 months
Eligibility Criteria
• Patients: Fifty specimens of IDC obtained from patients who underwent mastectomy in General Surgery Department of Sohag Faculty of Medicine according to local Ethical Committee regulations, to be examined in the Pathology Laboratory of the same faculty.
You may not qualify if:
- Patients received pre-operative chemotherapy or radiotherapy.
- Patients with insufficient clinical data.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Sohag Universitylead
Study Sites (2)
Faculty of Medicine, Sohag University
Sohag, Egypt
Faculty of Medicine, Sohag University
Sohag, Egypt
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- OTHER
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Lecturer at Pathology Department, Faculty of Medicine, Sohag University
Study Record Dates
First Submitted
April 30, 2021
First Posted
May 5, 2021
Study Start
May 1, 2021
Primary Completion
November 1, 2021
Study Completion
December 1, 2021
Last Updated
May 10, 2021
Record last verified: 2021-05